Reactions to Allergy Shots: How Patterns Change Across Treatment

For most patients, reactions to allergy shots decrease in frequency and severity as treatment progresses. During build-up, each dose escalation is new territory for the immune system, producing higher per-injection reaction rates. As IgG4 blocking antibodies rise — increasing 10 to 100-fold during SCIT treatment (Aalberse et al. 2009) — the immune response to each dose becomes more controlled. However, reactions can spike at predictable transition points regardless of how long a patient has been in treatment: new-vial changes carry elevated reaction risk (50% dose reduction is recommended), and pollen season overlap primes tissue mast cells to respond more intensely to previously tolerated maintenance doses. A prior systemic reaction is the strongest predictor of future systemic reactions (Roy 2007, 4-fold increased rate).

Recurrent large local reactions (LLRs) — swelling larger than a quarter (2.5 cm) at the injection site across multiple visits — are a clinically important pattern that warrants active management. While a single LLR does not predict systemic reactions (Tankersley 2000), the REPEAT Study (Calabria 2011, Ann Allergy) found that patients with frequent recurrent LLRs experienced at least one systemic reaction in 41.7% of cases, compared to 10.7% of non-LLR patients. If you are consistently getting large local reactions, discuss these options with your allergist: antihistamine premedication before each injection (can reduce LLR size by 30-50%), dose reduction at each escalation step, or modified escalation schedule. Documenting the size and timing of each LLR gives your allergist the data needed to make these decisions.

Late reactions after a period of uneventful injections are most commonly associated with new-vial transitions or pollen-season overlap. When a new vial of allergen extract is opened, the fresh concentrate may have higher biological potency than the end of the previous vial, triggering a stronger reaction at the same dose. The AAAAI/ACAAI Practice Parameter recommends a 50% dose reduction at every new vial specifically because of this risk. During peak pollen season, repeated environmental allergen exposure primes tissue mast cells, lowering the systemic reaction threshold for your maintenance dose. Counterintuitively, 59% of SCIT fatalities occurred during the maintenance phase (Bernstein 2004), concentrated around these transition moments — which is why consistent dose adjustment protocols matter even for long-established patients.

Dose adjustment after a systemic reaction follows a protocol graded by reaction severity, though no universally standardized schedule exists. The 2011 AAAAI/ACAAI Practice Parameter provides common conventions: after a Grade 1 systemic reaction, the dose is typically reduced to approximately 50% of the reaction-causing dose (or one step back). After a Grade 2 systemic reaction, the dose is reduced to approximately 10% of the reaction-causing dose (two to three dilution steps back). After a Grade 3 systemic reaction, a 10-fold dilution is recommended, with formal reconsideration of whether to continue SCIT. These reductions apply to the starting point for the next dose escalation — the patient then re-escalates from that lower starting point. New-vial transitions also call for a 50% dose reduction regardless of prior reactions.

Yes, both in mechanism and statistical profile. Build-up reactions are driven by dose escalation into territory where IgG4 blocking antibodies have not yet developed to compete with IgE for allergen binding. They tend to be more frequent per injection but are usually mild to moderate. Maintenance reactions are driven by specific transition events — new vials with fresh concentrate, pollen-season priming, or cofactors like exercise or uncontrolled asthma — rather than systematic dose escalation. Maintenance fatalities, counterintuitively, outnumber build-up fatalities (59% vs 41% per Bernstein 2004) despite a lower baseline per-injection systemic reaction rate. The risk in maintenance is concentrated at predictable moments, which is why dose-adjustment protocols for vial changes and seasonal reductions exist specifically for maintenance-phase patients.